Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL
Abstract
Simple Summary
Abstract
1. Introduction
2. Clinical Presentation
3. Diagnostic Procedures
4. Standard CSF Diagnostics
5. Cytology and Flow Cytometry
6. Free Light Chains
7. IL-10 and IL-6
8. CXCL13
9. MYD88
10. IgH Gene Rearrangement
11. microRNAs
12. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Ferreri, A.J.; Marturano, E. Primary CNS lymphoma. Best Pr. Res. Clin. Haematol. 2012, 25, 119–130. [Google Scholar] [CrossRef]
- Carnevale, J.; Rubenstein, J.L. The Challenge of Primary Central Nervous System Lymphoma. Hematol. Clin. North Am. 2016, 30, 1293–1316. [Google Scholar] [CrossRef]
- Montserrat, E. Primary CNS lymphoma: In search of the evidence. Lancet Haematol. 2015, 2, e227–e228. [Google Scholar] [CrossRef]
- Paydas, S. Primary central nervous system lymphoma: Essential points in diagnosis and management. Med Oncol. 2017, 34, 61. [Google Scholar] [CrossRef]
- Schlegel, U. Primary CNS lymphoma. Ther. Adv. Neurol. Disord. 2009, 2, 93–104. [Google Scholar] [CrossRef] [PubMed]
- Nishihara, M.; Sasayama, T.; Kudo, H.; Kohmura, E. Morbidity of stereotactic biopsy for intracranial lesions. Kobe J. Med Sci. 2011, 56, E148–E153. [Google Scholar] [PubMed]
- Khatab, S.; Spliet, W.; Woerdeman, P.A. Frameless image-guided stereotactic brain biopsies: Emphasis on diagnostic yield. Acta Neurochir. 2014, 156, 1441–1450. [Google Scholar] [CrossRef] [PubMed]
- Malone, H.; Yang, J.; Hershman, D.L.; Wright, J.D.; Bruce, J.N.; Neugut, A.I. Complications Following Stereotactic Needle Biopsy of Intracranial Tumors. World Neurosurg. 2015, 84, 1084–1089. [Google Scholar] [CrossRef] [PubMed]
- Haldorsen, I.S.; Espeland, A.; Larsson, E.M. Central nervous system lymphoma:characteristic findings on traditional and ad-vanced imaging. Am. J. Neuroradiol. 2011, 32, 984–992. [Google Scholar] [CrossRef]
- Roth, P.; Wick, W.; Weller, M. Steroids in neurooncology: Actions, indications, side-effects. Curr. Opin. Neurol. 2010, 23, 597–602. [Google Scholar] [CrossRef]
- Baraniskin, A.; Deckert, M.; Schulte-Altedorneburg, G.; Schlegel, U.; Schroers, R. Current strategies in the diagnosis of diffuse large B-cell lymphoma of the central nervous system. Br. J. Haematol. 2012, 156, 421–432. [Google Scholar] [CrossRef]
- Schroers, R.; Baraniskin, A.; Heute, C.; Vorgerd, M.; Brunn, A.; Kuhnhenn, J.; Kowoll, A.; Alekseyev, A.; Schmiegel, W.; Schlegel, U.; et al. Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology. Eur. J. Haematol. 2010, 85, 520–528. [Google Scholar] [CrossRef]
- Onda, K.; Wakabayashi, K.; Tanaka, R.; Takahashi, H. Intracranial malignant lymphomas: Clinicopathological study of 26 au-topsy cases. Brain Tumor Pathol. 1999, 16, 29–35. [Google Scholar] [CrossRef] [PubMed]
- Canovi, S.; Campioli, D. Accuracy of flow cytometry and cytomorphology for the diagnosis of meningeal involvement in lymphoid neoplasms: A systematic review. Diagn. Cytopathol. 2016, 44, 841–856. [Google Scholar] [CrossRef] [PubMed]
- Hildebrandt, B.; Müller, C.; Pezzutto, A.; Daniel, P.; Dörken, B.; Scholz, C. Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis—A pilot study. BMC Cancer 2007, 7, 185. [Google Scholar] [CrossRef] [PubMed]
- Schroers, R.; Baraniskin, A.; Heute, C.; Kuhnhenn, J.; Alekseyev, A.; Schmiegel, W.-H.; Schlegel, U.; Pels, H.-J. Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas. Eur. J. Haematol. 2010, 85, 236–242. [Google Scholar] [CrossRef] [PubMed]
- Sasayama, T.; Nakamizo, S.; Nishihara, M.; Kawamura, A.; Tanaka, H.; Mizukawa, K.; Miyake, S.; Taniguchi, M.; Hosoda, K.; Kohmura, E. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL). Neuro Oncol. 2011, 14, 368–380. [Google Scholar] [CrossRef]
- Nguyen-Them, L.; Costopoulos, M.; Tanguy, M.-L.; Houillier, C.; Choquet, S.; Benanni, H.; Elias-Shamieh, R.; Armand, M.; Faivre, G.; Glaisner, S.; et al. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients. Eur. J. Cancer 2016, 61, 69–76. [Google Scholar] [CrossRef]
- Sasagawa, Y.; Akai, T.; Tachibana, O.; Iizuka, H. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lym-phoma of the central nervous system. J. Neurooncol. 2015, 121, 177–183. [Google Scholar] [CrossRef]
- Shao, J.; Chen, K.; Li, Q.; Ma, J.; Ma, Y.; Lin, Z.; Kang, H.; Chen, B. High Level of IL-10 in Cerebrospinal Fluid is Specific for Diagnosis of Primary Central Nervous System Lymphoma. Cancer Manag. Res. 2020, 12, 6261–6268. [Google Scholar] [CrossRef]
- Bonzheim, I.; Giese, S.; Deuter, C.; Süsskind, D.; Zierhut, M.; Waizel, M.; Szurman, P.; Federmann, B.; Schmidt, J.; Quintanilla-Martinez, L.; et al. High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: A valuable tool to improve diagnostic yield of vit-reous aspirates. Blood 2015, 126, 76–79. [Google Scholar] [CrossRef] [PubMed]
- Song, Y.; Zhang, W.; Zhang, L.; Wu, W.; Zhang, Y.; Han, X.; Yang, C.; Zhang, L.; Zhou, D. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Ac-curate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma. Sci Rep. 2016, 6, 38671. [Google Scholar] [CrossRef] [PubMed]
- Costopoulos, M.; Kim, R.; Choquet, S.; Maloum, K.; Houillier, C.; Algrin, C.; Settegrana, C.; Villemonteix, J.; Brissard, M.; Quiney, C.; et al. Cerebrospinal fluid interleukin (IL)-10 and IL-10:IL-6 ratio as biomarkers for small B-cell lymphoproliferations with lep-tomeningeal dissemination. Semin Hematol. 2018, 55, 179–181. [Google Scholar] [CrossRef]
- Mu, P.; Han, Y.-C.; Betel, D.; Yao, E.; Squatrito, M.; Ogrodowski, P.; De Stanchina, E.; D’Andrea, A.; Sander, C.; Ventura, A. Genetic dissection of the miR-17 92 cluster of microRNAs in Myc-induced B-cell lymphomas. Genes Dev. 2009, 23, 2806–2811. [Google Scholar] [CrossRef] [PubMed]
- Rimelen, V.; Ahle, G.; Pencreach, E.; Zinniger, N.; Debliquis, A.; Zalmaï, L.; Harzallah, I.; Hurstel, R.; Alamome, I.; Lamy, F.; et al. Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis. Acta Neuropathol. Commun. 2019, 7, 43. [Google Scholar] [CrossRef] [PubMed]
- Postel, M.; Roosen, A.; Laurent-Puig, P.; Taly, V.; Wang-Renault, S.-F. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: A cancer diagnostic perspective. Expert Rev. Mol. Diagn. 2018, 18, 7–17. [Google Scholar] [CrossRef]
- Zajdel, M.; Rymkiewicz, G.; Sromek, M.; Cieslikowska, M.; Swoboda, P.; Kulinczak, M.; Goryca, K.; Bystydzienski, Z.; Blachnio, K.; Ostrowska, B.; et al. Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas. Cancers 2019, 11, 1647. [Google Scholar] [CrossRef]
- Ekstein, D.; Ben-Yehuda, D.; Slyusarevsky, E.; Lossos, A.; Linetsky, E.; Siegal, T. CSF analysis of IgH gene rearrangement in CNS lymphoma: Relationship to the disease course. J. Neurol. Sci. 2006, 247, 39–46. [Google Scholar] [CrossRef]
- Troppan, K.; Wenzl, K.; Deutsch, A.; Ling, H.; Neumeister, P.; Pichler, M. MicroRNAs in diffuse large B-cell lymphoma: Implications for pathogenesis, diagnosis, prognosis and therapy. Anticancer. Res. 2014, 34, 557–564. [Google Scholar]
- Mosser, D.M.; Zhang, X. Interleukin-10: New perspectives on an old cytokine. Immunol. Rev. 2008, 226, 205–218. [Google Scholar] [CrossRef]
- Hoekzema, R.; Murray, P.I.; van Haren, M.A.; Helle, M.; Kijlstra, A. Analysis of interleukin-6 in endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 1991, 32, 88–95. [Google Scholar]
- Geng, M.; Song, Y.; Xiao, H.; Wu, Z.; Deng, X.; Chen, C.; Wang, G. Clinical significance of interleukin-10 concentration in the cerebrospi-nal fluid of patients with primary central nervous system lymphoma. Oncol Lett. 2021, 21. [Google Scholar] [CrossRef]
- Ungureanu, A.; Le Garff-Tavernier, M.; Costopoulos, M.; Parratte, T.; Brinet, A.; Durand, H.; Gaultier, C.; Hurstel, R.; Alamome, I.; Sellal, F.; et al. CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma. J. Neurol. 2021, 1–5. [Google Scholar] [CrossRef]
- Ansel, K.; Harris, R.B.; Cyster, J.G. CXCL13 Is Required for B1 Cell Homing, Natural Antibody Production, and Body Cavity Immunity. Immunity 2002, 16, 67–76. [Google Scholar] [CrossRef]
- Rubenstein, J.L.; Wong, V.S.; Kadoch, C.; Gao, H.-X.; Barajas, R.; Chen, L.; Josephson, S.A.; Scott, B.; Douglas, V.; Maiti, M.; et al. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood 2013, 121, 4740–4748. [Google Scholar] [CrossRef]
- Mabray, M.C.; Barajas, R.F.; Villanueva-Meyer, J.E.; Zhang, C.A.; Valles, F.E.; Rubenstein, J.L.; Cha, S. The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma. Am. J. Neuroradiol. 2016, 37, 74–79. [Google Scholar] [CrossRef] [PubMed]
- Best, M.G.; Sol, N.; Zijl, S.; Reijneveld, J.C.; Wesseling, P.; Wurdinger, T. Liquid biopsies in patients with diffuse glioma. Acta Neuropathol. 2015, 129, 849–865. [Google Scholar] [CrossRef] [PubMed]
- Roschewski, M.; Dunleavy, K.; Pittaluga, S.; Moorhead, M.; Pepin, F.; Kong, K.; Shovlin, M.; Jaffe, E.S.; Staudt, L.M.; Lai, C.; et al. Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study. Lancet Oncol. 2015, 16, 541–549. [Google Scholar] [CrossRef]
- Fukumura, K.; Kawazu, M.; Kojima, S.; Ueno, T.; Sai, E.; Soda, M.; Ueda, H.; Yasuda, T.; Yamaguchi, H.; Lee, J.; et al. Genomic characteriza-tion of primary central nervous system lymphoma. Acta Neuropathol. 2016, 131, 865–875. [Google Scholar] [CrossRef] [PubMed]
- Nakamura, T.; Tateishi, K.; Niwa, T.; Matsushita, Y.; Tamura, K.; Kinoshita, M.; Tanaka, K.; Fukushima, S.; Takami, H.; Arita, H.; et al. Re-current mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas. Neuropathol. Appl. Neurobiol. 2016, 42, 279–290. [Google Scholar] [CrossRef] [PubMed]
- Hattori, K.; Sakata-Yanagimoto, M.; Okoshi, Y.; Goshima, Y.; Yanagimoto, S.; Nakamoto-Matsubara, R.; Sato, T.; Noguchi, M.; Takano, S.; Ishikawa, E. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma. Br. J. Haematol. 2017, 177, 492–494. [Google Scholar] [CrossRef]
- Varettoni, M.; Arcaini, L.; Zibellini, S.; Boveri, E.; Rattotti, S.; Riboni, R.; Corso, A.; Orlandi, E.; Bonfichi, M.; Gotti, M.; et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström’s macroglobulinemia and related lymphoid neoplasms. Blood 2013, 121, 2522–2528. [Google Scholar] [CrossRef]
- Zhou, Y.; Liu, W.; Xu, Z.; Zhu, H.; Xiao, D.; Su, W.; Zeng, R.; Feng, Y.; Duan, Y.; Zhou, J.; et al. Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes. Neoplasia 2018, 20, 1059–1069. [Google Scholar] [CrossRef]
- Hiemcke-Jiwa, L.S.; Leguit, R.J.; Snijders, T.J.; Jiwa, N.M.; Kuiper, J.J.; de Weger, R.A.; Minnema, M.C.; Huibers, M.M. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities. Crit. Rev. Oncol. 2018, 127, 56–65. [Google Scholar] [CrossRef]
- Hiemcke-Jiwa, L.S.; Minnema, M.C.; Loon, J.H.R.-V.; Jiwa, N.M.; De Boer, M.; Leguit, R.J.; De Weger, R.A.; Huibers, M.M. The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid. Hematol. Oncol. 2018, 36, 429–435. [Google Scholar] [CrossRef]
- Hattori, K.; Sakata-Yanagimoto, M.; Suehara, Y.; Yokoyama, Y.; Kato, T.; Kurita, N.; Nishikii, H.; Obara, N.; Takano, S.; Ishikawa, E.; et al. Clinical significance of disease-specificMYD88mutations in circulating DNA in primary central nervous system lymphoma. Cancer Sci. 2017, 109, 225–230. [Google Scholar] [CrossRef] [PubMed]
- Hohaus, S.; Giachelia, M.; Massini, G.; Mansueto, G.; Vannata, B.; Bozzoli, V.; Criscuolo, M.; D’Alò, F.; Martini, M.; Larocca, L.M.; et al. Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann. Oncol. 2009, 20, 1408–1413. [Google Scholar] [CrossRef] [PubMed]
- Mihailovich, M.; Bremang, M.; Spadotto, V.; Musiani, D.; Vitale, E.; Varano, G.; Zambelli, F.; Mancuso, F.M.; Cairns, D.A.; Pavesi, G.; et al. miR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat Commun. 2015, 6, 8725. [Google Scholar] [CrossRef]
- Baraniskin, A.; Kuhnhenn, J.; Schlegel, U.; Chan, A.; Deckert, M.; Gold, R.; Maghnouj, A.; Zöllner, H.; Reinacher-Schick, A.; Schmiegel, W.; et al. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 2011, 117, 3140–3146. [Google Scholar] [CrossRef] [PubMed]
- Baraniskin, A.; Kuhnhenn, J.; Schlegel, U.; Schmiegel, W.; Hahn, S.; Schroers, R. MicroRNAs in cerebrospinal fluid as biomarker for dis-ease course monitoring in primary central nervous system lymphoma. J. Neurooncol. 2012, 109, 239–244. [Google Scholar] [CrossRef] [PubMed]
- Wei, D.; Wan, Q.; Li, L.; Jin, H.; Liu, Y.; Wang, Y.; Zhang, G. Micro-RNAs as potential biomarkers for diagnosing cancers of central nerv-ous system: A meta-analysis. Mol. Neurobiol. 2015, 51, 1452–1461. [Google Scholar] [CrossRef] [PubMed]
- Mao, X.; Sun, Y.; Tang, J. Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma. Neurol. Sci. 2014, 35, 233–238. [Google Scholar] [CrossRef]
- Baraniskin, A.; Zaslavska, E.; Nöpel-Dünnebacke, S.; Ahle, G.; Seidel, S.; Schlegel, U.; Schmiegel, W.; Hahn, S.; Schroers, R. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for primary central nervous system lymphoma. Neuro Oncol. 2016, 18, 361–367. [Google Scholar] [CrossRef]
- Thapa, D.R.; Hussain, S.K.; Tran, W.C.; D’souza, G.; Bream, J.H.; Achenback, C.J.; Ayyavoo, V.; Detels, R.; Martínez-Maza, O. Serum mi-croRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL. J. Acquir. Immune Defic. Syndr. 2014, 66, 229–237. [Google Scholar] [CrossRef] [PubMed]
- Ferreri, A.J.M.; Calimeri, T.; Lopedote, P.; Francaviglia, I.; Daverio, R.; Iacona, C.; Belloni, C.; Steffanoni, S.; Gulino, A.; Anghileri, E.; et al. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: Results from a prospective study. Br. J. Haematol. 2021, 193, 497–505. [Google Scholar] [CrossRef] [PubMed]
Biomarker/Method | Body Fluid | Number of Patients | Sensitivity (%) | Specificity (%) | References |
---|---|---|---|---|---|
cytology | CSF | 37 | 13.30 | - | Schroers et al. [12] |
flow cytometry | CSF | 37 | 23.3 | - | Schroers et al. [12] |
Biomarker/Method. | Number of Patients | Body Fluid | Sensitivity (%) | Specificity (%) | References |
---|---|---|---|---|---|
FLC concentrations/ratios | 21 | CSF | 52.3 | - | Schroers et al. [16] |
IL-10 (cut-off 9.5 pg/mL) | 66 | CSF | 71 | 100 | Sasayama et al. [17] |
IL-10 (cut-off 4 pg/mL) | 119 | CSF | 88.6 | 88.9 | Nguyen-Them et al. [18] |
IL-10 (cut-off 8.2 pg/mL) | 102 | CSF | 95.5 | 96.1 | Song et al. [19] |
IL-10 (cut-off 8.3 pg/mL) | 108 | CSF | 59 | 98 | Shao et al. [20] |
IL-10/IL-6 ratio (cut-off 1.6 pg/mL) | 108 | CSF | 66 | 91 | Shao et al. [20] |
IL-10/IL-6 ratio (cut-off 0,72 pg/mL) | 102 | CSF | 95.5 | 100 | Song et al. [19] |
IgH gene rearrangement | 32 | CSF | 54 | 97 | Eckstein et al. [21] |
CXCL13 | 220 | CSF | 69.9 | 92.7 | Rubenstein et al. [22] |
Combination of CXCL13 and IL-10 | 77 | CSF | 76.7 | 90.9 | Mabray et al. [23] |
MYD88 | 225 | CSF | 72 | - | Ferreri et al. [24] |
Combination of MYD88 and IL-10 | 225 | CSF | 94 | 98 | Ferreri et al. [24] |
MYD88 | 90 | vitreous | 69 | 100 | Bonzheim et al. [25] |
microRNA (miR-21, -19b, and -92) | 53 | CSF | 95.7 | 96.7 | Baraniskin et al. [26] |
microRNA (miR-21, -19b, and -92) | 53 | CSF | 63.3 | 80.7 | Zajdel et al. [27] |
Combination of RNU2-1f and miR-21 | 119 | CSF | 91.7 | 95.7 | Baraniskin et al. [28] |
miR-222 | 150 | serum | 80 | 82 | Thapa et al. [29] |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Baraniskin, A.; Schroers, R. Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL. Cancers 2021, 13, 2665. https://doi.org/10.3390/cancers13112665
Baraniskin A, Schroers R. Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL. Cancers. 2021; 13(11):2665. https://doi.org/10.3390/cancers13112665
Chicago/Turabian StyleBaraniskin, Alexander, and Roland Schroers. 2021. "Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL" Cancers 13, no. 11: 2665. https://doi.org/10.3390/cancers13112665
APA StyleBaraniskin, A., & Schroers, R. (2021). Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL. Cancers, 13(11), 2665. https://doi.org/10.3390/cancers13112665